Abstract
Bedaquiline (Sirturo—Janssen) received accelerated approval from FDA late last year for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. Bedaquiline is an inhibitor of mycobacterial ATP (adenosine-5'-triphosphate) synthase, an enzyme that is essential for the generation of energy in <i>Mycobacterium tuberculosis</i>. Its use should be reserved for patients who cannot otherwise be provided with an effective treatment regimen, and the drug should be administered by directly observed therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
